| Patent Number |
Title Of Patent |
Date Issued |
| RE35694 |
Polypeptide cartilage-inducing factors found in bone |
December 16, 1997 |
| Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 dalto |
| RE34090 |
Polypeptide cartilage-inducing factors found in bone |
October 6, 1992 |
| Two proteins that are found is bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 dalto |
| 6743446 |
Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-rele |
June 1, 2004 |
| Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method c |
| 5693341 |
Affinity bound collagen matrices for the delivery of biologically active agents |
December 2, 1997 |
| Affinity bound collagen matrices for the delivery of biologically active agents, and methods for preparing such matrices, are disclosed. A preferred method for preparing the matrices of the invention comprises mixing a binding ligand and an active agent together, allowing the resulti |
| 5550188 |
Polymer conjugates ophthalmic devices comprising collagen-polymer conjugates |
August 27, 1996 |
| Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type |
| 5543441 |
Implants coated with collagen-polymer conjugates |
August 6, 1996 |
| Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer. |
| 5523348 |
Method of preparing collagen-polymer conjugates |
June 4, 1996 |
| Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer. |
| 5446091 |
Collagen-polymer conjugates containing an ether linkage |
August 29, 1995 |
| Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type |
| 5413791 |
Collagen-polymer conjugates |
May 9, 1995 |
| Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type |
| 5393739 |
Use of bone morphogenetic protein in synergistic combination with TGF-.beta. for bone repair |
February 28, 1995 |
| Bone morphogenetic proteins -2 and -3 (BMPs -2 and -3) work in synergistic combination with TGF-.beta.z to provide compositions with increased osteogenic activity. Methods of treating bone defects, inducing bone growth and increasing bone marrow cell production using these compositions |
| 5376375 |
Method of augmenting tissue using collagen-polymer conjugates |
December 27, 1994 |
| Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer. |
| 5328955 |
Collagen-polymer conjugates |
July 12, 1994 |
| Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type |
| 5324775 |
Biologically inert, biocompatible-polymer conjugates |
June 28, 1994 |
| Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding biologically inactive, natural, biocompatible polymer to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide biocompatible conjugates. The synthet |
| 5306500 |
Method of augmenting tissue with collagen-polymer conjugates |
April 26, 1994 |
| Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer. |
| 5304595 |
Collagen-polymer conjugates |
April 19, 1994 |
| Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer. |
| 5264214 |
Composition for bone repair |
November 23, 1993 |
| Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer. |
| 5162430 |
Collagen-polymer conjugates |
November 10, 1992 |
| Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer. |
| 4971952 |
Method of treating inflammation with cartilage inducing factor |
November 20, 1990 |
| Inflammation, acute and/or chronic, is treated with a CIF (TGF-beta). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration of activator or cofactor for efficacy. |
